Skip to main content
Kris MG on Muck Rack

Kris MG

As seen in: Nature, PeerJ
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kris

Contact Kris, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis

|
By Kris MG, Kim HC, Lee KH
| PeerJ
Hongxia Xu conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft. Jiankun Xing conceived and designed the experiments, performed the experiments, prepared figures and/or tables, and approved the final draft. Shaohui Yang conceived and designed the experiments, performed the experiments, prepared figures and/or tables, and approved the final draft.
Open in Who Shared View Duplicates (2) Issue with article?

Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives

|
By Kris MG, Mark G. Kris, Tetsuya Mitsudomi, Solange Peters
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (594) Issue with article?

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive <i>EGFR</i>-mutant non-small cell lung cancer

|
By Oxnard GR, Kris MG, Miller VA, Holodny AI
| Nature Verified
Osimertinib demonstrated promising efficacy for refractory leptomeningeal metastases (LM) in preclinical data and a clinical study at 160?mg, but there is limited data for the standard 80?mg dose. T790M-positive patients with suspected LM after classical epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) failure were enroled. We investigated 13 patients (5 definitive and 8 possible LM cases).
Open in Who Shared Issue with article?
See all 4 articles